Create your own free news widgets.

The Medicare Payment Advisory Commission on Friday examined some of the factors contributing to U.S. health care spending growth, CQ HealthBeat reports.read more

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the results from a multidisciplinary analysis of in vitro and in vivo data of LIALDA® (mesalamine) versus Asacol® (mesalamine) that investigated factors including transit and disintegration of tablets along with tablet coating thickness that may affect a consistent release of 5-aminosalicylate acid (5-ASA) in both therapies.

A splicing factor targets known cancer-related proteins A research team at Cold Spring Harbor Laboratory (CSHL) is clarifying a previously unappreciated way that cellular processes are disrupted in cancer. Last year, scientists from the same CHSL team discovered that a 'splicing factor' called SF2/ASF--a protein that changes the instructions for how other proteins are assembled--can induce tumors in cell cultures.

The adaptor protein Shc plays an important role in the activation of signalling pathways downstream of receptor tyrosine kinases (RTKs) regulating diverse cellular functions such as differentiation, adhesion, migration and mitogenesis. Despite being phosphorylated downstream of members of the fibroblast growth factor receptor (FGFR) family, a direct interaction of Shc with this receptor family has not been described to date. Various studies have suggested potential binding sites for the Shc PTB and/or SH2 domains on the FGFR1, but no interaction of full length Shc with these sites has been reported in vivo. We investigated the importance of the SH2 and PTB domains in recruitment of Shc to the FGFR2(IIIc) to characterise the interaction of these two proteins. Confocal microscopy revealed extensive co-localisation of Shc with the FGFR2. The PTB domain was identified as the critical component of Shc mediating membrane localisation. Data from fluorescent lifetime imaging microscopy (FLIM)

The finding is the latest evidence to suggest that a baby's sleep environment is a critical factor in the risk for sudden infant death syndrome.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the results from a multidisciplinary analysis of in vitro and in vivo data of LIALDA® (mesalamine) versus Asacol® (mesalamine) that investigated factors including transit and disintegration of tablets along with tablet coating thickness that may affect a consistent release of 5-aminosalicylate acid (5-ASA) in both therapies.

Almost half of U.S. households are worried about their family's basic needs, according to new data from the American Psychological ...